Healthcare Co. Welcomes Possible AI Funding Effort in Canada

  ()
Canadian artificial intelligence (AI) and machine learning healthcare company Treatment.com AI Inc. is using AI to positively disrupt the healthcare sector. Canada is planning to fund the industry in a big way.

Chen in Q2 2024: It's Silver, Again, as Precious Metal Breaks Out

  ()
After being bullish on silver for at least the last year, asset manager Chen Lin feels a little vindicated by the precious metal's recent two-year high.

Co. Adding 500 Patients to Its Mental Health Care Platform

  ()
This Canada-based health care technology firm is profitable and growing. Learn more about it here.

Analyst Encouraged by ON Gov's Decision To Sustain Fees

Research Report
  ()
CareRx Corp. will continue to receive funding for professional fees at the same levels as before for at least one more year, according to a Leede Jones Gable research note.

Biotech's Lawsuit With Eli Lilly Might Catalyze Stock

  ()
Nektar Therapeutics has commenced a Phase 2b clinical trial evaluating its lead product candidate rezpegaldesleukin in patients with severe to very severe alopecia areata. In other news, Nektar has a lawsuit pending against Eli Lilly & Co. Read on to see what two experts have to say about this biotech stock.

AI Co. Funded To Develop AI Approach to Health Equity

  ()
Treatment.com AI Inc. announced it has been granted funding from The National Institute of Health (NIH) to create a "culturally sensitive AI approach" when it comes to receiving familial medical histories for patients. Read on to see the medical need for this type of service and why one technical analysts is optimistic about this stock.

Healthcare Stock Has Reasonable Value Before Seasonal Profit, Analyst Says

Research Report
  ()
K-Bro Linen Inc.'s FQ23 financial data supported its Buy rating, according to a Leede Jones Gable research note.

AI Medical App Passes Standard Student Test

  ()
This software is one of a suite offered by this health care technology firm. Learn about its other products and the growing sector.

Biotech Co.'s Target Price Significantly Higher Than Current

Research Report
  ()
Biofrontera Inc. is currently trading at US$1.26, but has a target price of US$26, according to a Roth MKM research note.

Biotech Stocks Break Out

Contributed Opinion
  ()
Ron Struthers of Struthers Stock Report shares that the S&P Biotech SPDR is over 60% this year and trading around $100 a share. He also details how well he has down, buying under valued cash-rich biotechs in 2023, and shares one stock he believes it worth looking into.

Is This Pharma Set To Break Out After COPD Drug Approval?

  ()
Clinical-stage biopharmaceutical company Verona Pharma Plc is looking toward a pivotal year as its new chronic obstructive pulmonary disease (COPD) drug ensifentrine nears possible approval by the FDA. At least two research companies have named it a top pick for 2024.

This Biotech Is a Potential Disruptor, Expert Says

Contributed Opinion
  ()
Chris Temple of The National Investor shares why he believes BetterLife Pharma Inc. is an Immediate Buy.

Safe Supply Firm Announces Another Promising Acquisition

  ()
Safe Supply Streaming Co. adds another company to its portfolio, and continues advocating for harm reduction in the psychedelic sector.

Healthcare AI Firm Has 'Bright Future,' Analyst Predicts

  ()
Canadian artificial intelligence (AI) and machine learning healthcare firm Treatment.com AI is breaking into the global healthcare AI market predicted to be worth US$187 billion by the end of the decade.

NY Biotech Has Potentially Game Changing Anxiety Therapy

Research Report
  ()
Mind Medicine (MindMed) Inc. recently announced positive results from its Phase 2b trial of MM120 in generalized anxiety disorder, according to a Roth MKM research note.

Bionic Medical Co. Has Sufficient Funds to Operate Through 2024

Research Report
  ()
Ekso Bionics Holdings Inc.'s fourth quarter of 2023 financial results were in line with estimates, according to H.C. Wainwright & Co.

Expert Investing Ideas

"RHT is rated an Immediate Buy here."

–Clive Maund, CliveMaund.com


Streetwise Key Charts
Pharma Biotech & Life Sci

Get Our Streetwise Reports' Life Sciences Report Newsletter Free and be the first to know!

A valid email address is required to subscribe

'Safe Supply' Co. Secures Legal Flow of Coca Products

  ()
This is a milestone for the venture capital firm investing in efforts that address the toxic drug crisis in Canada and the U.S. Learn more about the company and the latest wave of drug reform.

Alt-Pharma VC adds 7% Stake in Testing Strip Firm

  ()
Alt pharma is hot these days, and few companies are coming in hotter than Safe Supply Streaming Co. Ltd., which just secured a 7% stake in a leading medical test company to expand its functional portfolio.

Wellness Co. Preparing for US Legislation

Research Report
  ()
Wellness company Canopy Growth Corp. is taking steps forward while it waits for the U.S. to make legislative changes, according to a Roth MKM research note.

Cash Rich Biotech Could Win a Lawsuit With Lilly, Expert Says

Contributed Opinion
  ()
Ron Struthers explains how the cash value of this biotech is about $1.68/share and the stock is selling at around -58% discount to cash value. He also discusses a recent lawsuit with Eli Lilly.

Drug Reformer Subsidiary Inspected for Dealer License

  ()
In a "transformative moment" for the company, a Safe Supply Streaming Co. Ltd. subsidiary has undergone an official inspection by Health Canada to acquire a dealer license to produce, distribute, and export controlled substances.